We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher (DHR) Surpasses Q4 Earnings and Sales Estimates
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) reported better-than-expected results for the fourth quarter of 2019, with earnings and sales surpassing estimates by 2.4% and 1.7%, respectively.
The company’s adjusted earnings were $1.28 per share in the reported quarter, which outpaced the Zacks Consensus Estimate of $1.25. The same also grew 12.3% from the year-ago quarter’s figure of $1.14 on sales growth and margin improvement.
For 2019, the company’s adjusted earnings were $4.42 per share, increasing 9.1% year over year. However, the bottom line lagged the Zacks Consensus Estimate of $4.67.
Segmental Sales
In the quarter under review, the company’s net sales were $4,868.4 million, which grew 5.7% from the year-ago quarter. Organic sales in the quarter grew 6% and acquired assets had a positive 0.5% impact. However, foreign-currency translations had a negative impact of 1%.
Also, the company’s top line surpassed the Zacks Consensus Estimate of $4,787 million.
Effective third-quarter 2019, the company started reporting net sales under three segments — Life Sciences, Diagnostics, and Environmental & Applied Solutions. The segmental information is briefly discussed below:
Revenues for the Life Sciences segment totaled $1,916 million, rising 6.8% year over year. Results were driven by 1% gain from acquired assets and 6.5% growth in core sales, partially offset by a 0.5% adverse impact of foreign-currency translations.
Revenues in the Diagnostics segment grossed $1,804.5 million, increasing 7.1% year over year. The improvement came on the back of 8% rise in core sales, which was partially offset by a 1% negative impact of foreign-currency translations.
Revenues in the Environmental & Applied Solutions segment totaled $1,147.9 million, rising 1.9% year over year. The uptick can be attributed to 2.5% growth in core sales. However, foreign-currency translations had an adverse impact of 0.5%.
For 2019, the company’s net sales were $17.9 billion, reflecting growth of 5.1% from the previous year. However, the top line lagged the Zacks Consensus Estimate of $19.9 billion.
Margin Profile
In the quarter under review, Danaher’s cost of sales rose 4.5% year over year to $2,164.8 million. It represented 44.5% of net sales compared with 45% in the year-ago quarter. Gross margin increased 50 basis points (bps) year over year to 55.5%.
Selling, general and administrative expenses of $1,448.1 million reflect a year-over-year increase of 3.9%. As a percentage of net sales, it was 29.7%. Research and development expenses were $293.8 million, which rose 6.4% year over year. It represented 6% of net sales.
Operating income in the quarter under review grew 11.4% year over year to $961.7 million. Operating margin increased 100 bps to 19.8% in the quarter. The improvement was driven by the contribution of 175 bps from the core business, partially offset by 15-bps adverse impact of acquisitions and 60-bps impact of miscellaneous sources.
Interest expenses doubled year over year to $44.4 million.
Balance Sheet and Cash Flow
Exiting the fourth quarter, Danaher had cash and cash equivalents of $19,912.3 million, up 39.7% from $14,252.1 million at the end of the last reported quarter. Long-term debt balance rose 30.1% sequentially to $21,516.7 million.
In 2019, the company generated net cash of $3,657.4 million from operating activities, increasing 0.4% from the previous year. Capital used for purchasing property, plant and equipment totaled $635 million versus $583.5 million in the previous year.
In the year, the company paid out dividends worth $526.7 million to its shareholders.
Outlook
In the quarters ahead, Danaher expects to consistently benefit from Danaher Business System initiatives. These efforts enabled the company to focus more on product innovation, superior product quality, building an efficient workforce and enhancing shareholder value.
Also, Danaher anticipates completing the acquisition of General Electric Company's (GE - Free Report) BioPharma business in the first quarter of 2020. The buyout will likely strengthen the company's biologics workflow solutions business under its Life Sciences segment.
For the first quarter of 2020, Danaher anticipates adjusted earnings of $1.06-$1.09 per share.
For 2020, the company anticipates adjusted earnings per share of $4.80-$4.90. Core sales growth will likely be 5%.
Danaher Corporation Price, Consensus and EPS Surprise
In the past 60 days, earnings estimates for the two companies have improved for the current year. Further, positive earnings surprise for the last four quarters, on average, was 6.95% for SPX FLOW and 4.21% for Barnes.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Danaher (DHR) Surpasses Q4 Earnings and Sales Estimates
Danaher Corporation (DHR - Free Report) reported better-than-expected results for the fourth quarter of 2019, with earnings and sales surpassing estimates by 2.4% and 1.7%, respectively.
The company’s adjusted earnings were $1.28 per share in the reported quarter, which outpaced the Zacks Consensus Estimate of $1.25. The same also grew 12.3% from the year-ago quarter’s figure of $1.14 on sales growth and margin improvement.
For 2019, the company’s adjusted earnings were $4.42 per share, increasing 9.1% year over year. However, the bottom line lagged the Zacks Consensus Estimate of $4.67.
Segmental Sales
In the quarter under review, the company’s net sales were $4,868.4 million, which grew 5.7% from the year-ago quarter. Organic sales in the quarter grew 6% and acquired assets had a positive 0.5% impact. However, foreign-currency translations had a negative impact of 1%.
Also, the company’s top line surpassed the Zacks Consensus Estimate of $4,787 million.
Effective third-quarter 2019, the company started reporting net sales under three segments — Life Sciences, Diagnostics, and Environmental & Applied Solutions. The segmental information is briefly discussed below:
Revenues for the Life Sciences segment totaled $1,916 million, rising 6.8% year over year. Results were driven by 1% gain from acquired assets and 6.5% growth in core sales, partially offset by a 0.5% adverse impact of foreign-currency translations.
Revenues in the Diagnostics segment grossed $1,804.5 million, increasing 7.1% year over year. The improvement came on the back of 8% rise in core sales, which was partially offset by a 1% negative impact of foreign-currency translations.
Revenues in the Environmental & Applied Solutions segment totaled $1,147.9 million, rising 1.9% year over year. The uptick can be attributed to 2.5% growth in core sales. However, foreign-currency translations had an adverse impact of 0.5%.
For 2019, the company’s net sales were $17.9 billion, reflecting growth of 5.1% from the previous year. However, the top line lagged the Zacks Consensus Estimate of $19.9 billion.
Margin Profile
In the quarter under review, Danaher’s cost of sales rose 4.5% year over year to $2,164.8 million. It represented 44.5% of net sales compared with 45% in the year-ago quarter. Gross margin increased 50 basis points (bps) year over year to 55.5%.
Selling, general and administrative expenses of $1,448.1 million reflect a year-over-year increase of 3.9%. As a percentage of net sales, it was 29.7%. Research and development expenses were $293.8 million, which rose 6.4% year over year. It represented 6% of net sales.
Operating income in the quarter under review grew 11.4% year over year to $961.7 million. Operating margin increased 100 bps to 19.8% in the quarter. The improvement was driven by the contribution of 175 bps from the core business, partially offset by 15-bps adverse impact of acquisitions and 60-bps impact of miscellaneous sources.
Interest expenses doubled year over year to $44.4 million.
Balance Sheet and Cash Flow
Exiting the fourth quarter, Danaher had cash and cash equivalents of $19,912.3 million, up 39.7% from $14,252.1 million at the end of the last reported quarter. Long-term debt balance rose 30.1% sequentially to $21,516.7 million.
In 2019, the company generated net cash of $3,657.4 million from operating activities, increasing 0.4% from the previous year. Capital used for purchasing property, plant and equipment totaled $635 million versus $583.5 million in the previous year.
In the year, the company paid out dividends worth $526.7 million to its shareholders.
Outlook
In the quarters ahead, Danaher expects to consistently benefit from Danaher Business System initiatives. These efforts enabled the company to focus more on product innovation, superior product quality, building an efficient workforce and enhancing shareholder value.
Also, Danaher anticipates completing the acquisition of General Electric Company's (GE - Free Report) BioPharma business in the first quarter of 2020. The buyout will likely strengthen the company's biologics workflow solutions business under its Life Sciences segment.
For the first quarter of 2020, Danaher anticipates adjusted earnings of $1.06-$1.09 per share.
For 2020, the company anticipates adjusted earnings per share of $4.80-$4.90. Core sales growth will likely be 5%.
Danaher Corporation Price, Consensus and EPS Surprise
Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation Quote
Zacks Rank & Stock to Consider
With a market capitalization of $117.6 billion, the company currently carries a Zacks Rank #3 (Hold).
Two better-ranked stocks in the Zacks Industrial Products sector are SPX FLOW, Inc. (FLOW - Free Report) and Barnes Group, Inc. (B - Free Report) . While SPX FLOW currently sports a Zacks Rank #1 (Strong Buy), Barnes carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, earnings estimates for the two companies have improved for the current year. Further, positive earnings surprise for the last four quarters, on average, was 6.95% for SPX FLOW and 4.21% for Barnes.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>